RGC
Regencell BioscienceCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful program progress or strategic deal drives re-rating toward analyst high; limited coverage means upside can be rapid if news is favorable.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.9.
What can break
Clinical or operational setbacks without clear remediation would materially erode value and justify the bear target.
Momentum
28
Value
41
Sentiment
84
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $31.13 · Bull $35.17 · Bear $26.67
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-16 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Why
Momentum28 · Δ7d -18.0
Value41 · Δ7d +0.1
Sentiment84 · Δ7d +11.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
28
34% active weight
Current posture
7d trendSoftening
Δ7d
-18.0
Δ21d
-43.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
84
33% active weight
Current posture
7d trendImproving
Δ7d
+11.9
Δ21d
+24.0
Why this grade
Composite grade C. Momentum 28.5 / Value 41.1 / Sentiment 83.5
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$11.47B
Beta
2.02
Shares Out
494.49M
P/E (TTM) · Derived
-3221.7
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
-
EPS YoY
+22.6%
Gross Margin
-
Op Margin
-
Net Debt
-$4.9M
Current Ratio
7.39
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology